A Letter from the President
Dear Readers
David G. Nathan, M.D.
This issue of Paths of Progress is devoted largely to the subject of cancer research.
Research has always been at the core of Dana-Farber's mission, and with good reason. Without research in the laboratory and in the clinic, we would forever be at a stalemate in the battle against cancer.
In the following pages, you will read about a vitally important, but often unheralded, aspect of cancer research — clinical research or, put more simply, studies involving patients. In addition to learning about the clinical trials process, you will read some compelling stories about patients who, often for very different reasons, have taken part in investigations designed to answer important questions about therapies. These women and men are truly the unsung heroes of cancer research, without whom real progress would not be possible.
An article in this edition describes an unprecedented collaboration in cancer research called the Dana-Farber/Harvard Cancer Center, which combines the vast talents and resources of seven Harvard-affiliated institutions. Supported in part by a major National Cancer Institute grant, this new center brings together some of the brightest, most creative minds in the world to focus exclusively on the problem of cancer.
You will also read a feature on cancer and aging that highlights some fascinating research at Dana-Farber aimed at better understanding the molecular and cellular processes that make the elderly far more likely to develop cancer than younger adults or children. As the U.S. population ages, this work has the potential to affect millions of Americans.
In the next issue of Paths of Progress, this page will carry a message from my successor, Edward J. Benz Jr., M.D. Dr. Benz, whom we introduce to you on page 2, is uniquely qualified to carry on Dana-Farber's mission in research, patient care, training, and community service. We are truly fortunate to have him taking the helm of the Institute at such a pivotal time in the history of cancer prevention, diagnosis, and treatment.
I've had a wonderful time in my five years as president of Dana-Farber. My plans are now to pursue academic and clinical interests, but I will be available to Dr. Benz in an advisory role whenever he calls. I am overjoyed by his appointment and eager to assist with the transition to his leadership in any way possible.
I want to thank our readers for all their support over the years. I hope you enjoy this issue and, as always, encourage you to contact the editor with any comments or suggestions for future articles.
David G. Nathan, M.D.
President, Dana-Farber Cancer Institute